US 12,011,484 B2
Compound for the sequestration of undesirable antibodies in a patient
Oskar Smrzka, Vienna (AT); and Bettina Wanko, Vienna (AT)
Assigned to ABLEVIA BIOTECH GMBH, Vienna (AT)
Appl. No. 17/424,791
Filed by ABLEVIA BIOTECH GMBH, Vienna (AT)
PCT Filed Mar. 23, 2020, PCT No. PCT/EP2020/058024
§ 371(c)(1), (2) Date Jul. 21, 2021,
PCT Pub. No. WO2020/193486, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 19164784 (EP), filed on Mar. 23, 2019.
Prior Publication US 2022/0062435 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 47/64 (2017.01); A61P 37/06 (2006.01); C07K 17/06 (2006.01)
CPC A61K 47/6811 (2017.08) [A61K 47/643 (2017.08); A61P 37/06 (2018.01); C07K 17/06 (2013.01)] 10 Claims
 
1. A method of selective depletion of at least one undesirable anti-drug antibody (ADA), wherein the at least one ADA is an anti-alglucosidase alfa antibody, the method comprising the following steps:
(i) identifying at least one sequence fragment of alglucosidase alpha for which the at least one ADA is specific, wherein the at least one sequence fragment has a length of 7-13 amino acids; and
(ii) administering a pharmaceutical composition to an individual in need thereof, wherein the pharmaceutical composition is non-immunogenic in the individual, wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable excipient and
a compound comprising
a biopolymer scaffold and at least
a peptide Pa with a sequence length of 7-13 amino acids, wherein peptide Pa does not bind to any human leukocyte antigen (HLA) class I molecule, and
a peptide Pb with a sequence length of 7-13 amino acids, wherein peptide Pb does not bind to any HLA class I molecule;
wherein each of the peptides is bound to the biopolymer scaffold;
wherein the biopolymer scaffold is selected from the group consisting of a human albumin, a human haptoglobin and a human transferrin, and wherein at least peptide Pa is a circularized peptide;
wherein peptide Pa and peptide Pb independently comprise a sequence identical to the at least one sequence fragment of alglucosidase alfa.